ZEGFROVY® Gains FDA Accelerated Approval for NSCLC with EGFR Exon 20 Insertion Mutations with Thermo Fisher's Oncomine™ Dx as companion diagnostic test
Redosable, Eye Drop Gene Therapy KB803 Enters Phase 3 with First Patient Dosed by Krystal Biotech for Dystrophic Epidermolysis Bullosa Eye Complications